Synapse - Komal Jhaveri

Results (203)

A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER

Meeting Abstract

Jhaveri, K. L.; Jeselsohn, R.; Lim, E.; Hamilton, E. P.; Yonemori, K.; Beck, J. T.; Kaufman, P. A.; Sammons, S.; Bhave, M. A.; Saura, C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial

Meeting Abstract

Jhaveri, K. L.; Goldman, J. W.; Hurvitz, S. A.; Guerrero-Zotano, A.; Unni, N.; Brufsky, A.; Park, H.; Waisman, J. R.; Yang, E. S. H.; Spanggaard, I.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/ HER2-) metastatic breast cancer (BC)

Meeting Abstract

Bedard, P. L.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E. P.; Italiano, A.; Juric, D.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC)

Meeting Abstract

Andre, F.; Hamilton, E. P.; Loi, S.; Im, S. A.; Sohn, J.; Tseng, L. M.; Anders, C. K.; Schmid, P.; Boston, S.; Darilay, A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: Findings from the SUMMIT basket trial

Meeting Abstract

Goldman, J.; Bueno, A. M.; Dooms, C.; Jhaveri, K.; de Miguel, M. J.; Piha-Paul, S. A.; Unni, N.; Mahipal, A.; Suga, J. M.; Naltet, C.; more...
European Journal of Cancer (2022)

Fulltext@MSK | Save

Matching adjusted indirect comparison of PFS & OS comparing ribociclib + letrozole vs palbociclib + letrozole as first-line treatment of HR+/HER2− ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2

Meeting Abstract

Jhaveri, K.; O'Shaughnessy, J.; Fasching, P.; Cardoso, F.; Tolaney, S.; Hamilton, E.; Sharma, V. K.; Biswas, C.; Haftchenary, S.; Pathak, P.; more...
European Journal of Cancer (2022)

Fulltext@MSK | Save

Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

Journal Article

Rugo, H. S.; Bardia, A.; Marmé, F.; Cortes, J.; Schmid, P.; Loirat, D.; Trédan, O.; Ciruelos, E.; Dalenc, F.; Pardo, P. G.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Accelerating drug development in breast cancer: New frontiers for ER inhibition

Review

Ferraro, E.; Walsh, E. M.; Tao, J. J.; Chandarlapaty, S.; Jhaveri, K.
Cancer Treatment Reviews (2022)

Fulltext@MSK | Save

Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study